| Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. | |
| | |
MedLine Citation:
|
PMID: 20647417 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD). CASE SUMMARY: A 61-year-old obese man presented with jaundice, nausea, fatigue, and an unintentional weight loss 2 weeks following initiation of metformin. Laboratory findings revealed aminotransferase values 10-15 times the upper limit of normal. Potential causative agents, including metformin, simvastatin, and Niaspan (extended-release niacin), were discontinued. Two months later, the patient's signs and symptoms had resolved and aminotransferase values returned to normal. An objective causality assessment revealed that the adverse reaction was probably associated with metformin. DISCUSSION: Since numerous medications and disease states can cause abnormalities in liver enzymes, it is important for providers to be able to distinguish the cause(s) and take appropriate actions. This can take a great deal of time and effort in patients with multiple medications and comorbidities. In this patient's case, viral hepatitis, worsening NAFLD, and the concomitant drugs were highly suspected. As hydroxymethylglutaryl coenzyme A reductase inhibitors offer substantial cardiovascular benefits and as metformin is a first-line agent in helping to lower blood glucose concentrations and to normalize the metabolic profile in type 2 diabetes, reintroduction of metformin and simvastatin would likely be beneficial. CONCLUSIONS: This is a case report of metformin-induced hepatotoxicity. As the prevalence of type 2 diabetes and subsequent metabolic effects increases in the US, metformin use will likewise increase. As potential for increased idiosyncratic hepatotoxicity associated with metformin use is likely to occur, clinicians should be vigilant. |
| | |
Authors:
|
Catherine J Cone; Amy M Bachyrycz; Glen H Murata |
Related Documents
:
|
18319497 - Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. 10913727 - Weight gain associated with valproate in childhood. 20123087 - Metformin induces suppression of nad(p)h oxidase activity in podocytes. 9793597 - Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. 1890157 - Exaggerated early insulin release and insulin resistance in a diabetes-prone population... 9771447 - Haemoglobin le lamentin (alpha 20 (b1) his-->gln) in a british family: identification b... |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-08-31 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 44 ISSN: 1542-6270 ISO Abbreviation: Ann Pharmacother Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-24 Completed Date: 2011-01-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1655-9 Citation Subset: IM |
Affiliation:
|
University of New Mexico, Albuquerque, USA. CJCone@salud.unm.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
complications,
drug therapy* Drug-Induced Liver Injury / enzymology, etiology* Fatty Liver / drug therapy*, etiology Humans Hypoglycemic Agents / adverse effects*, therapeutic use Male Metformin / adverse effects*, therapeutic use Middle Aged Obesity / complications Transaminases / blood |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 657-24-9/Metformin; EC 2.6.1.-/Transaminases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thoughts and acts of aggression/violence toward others reported in association with varenicline.
Next Document: Long-range effects of histone point mutations on DNA remodeling revealed from computational analyses...